Arzeda, a Seattle, WA-based protein design company, closed its $15.2m Series A funding round.
The company raised an additional $3.2m since announcing an initial $12m raise on July 20.
Additional investors included Universal Materials Incubator Co., Ltd. (UMI) and Casdin Capital, LLC., which joined Series A lead investor OS Fund and Bioeconomy Capital, Sustainable Conversion Ventures, and seed investor WRF Capital. Arzeda’s board now includes Jeff Klunzinger, Co-Founder and General Partner at OS Fund.
The company will use the funds to expand the throughput capacity of its proprietary protein design platform and product development pipeline, with a focus on delivering novel proteins and biological pathways that are ready for commercial production.
Led by Alexandre Zanghellini, co-founder and CEO, Arzeda leverages an advanced protein design technology to develop a portfolio of enzymes and specialty chemicals for polymers, advanced materials and health and nutrition products.
The company serves global manufacturers, such as DuPont, Mitsubishi Chemical, INVISTA and others to improve crop yield and resilience. The close of the Series A comes as Arzeda is gaining traction in the synthetic biology and bioeconomy markets.